Overexpression of NSD2 has also been documented in multiple solid tumors, including breast, lung, renal, and gastric cancers, and is frequently amplified in multiple myeloma due to the t(4;14) translocation, where the NSD2 gene is under the control of the IgH promoter (59). The gene discussed is NSD2; the disease is plasma cell myeloma.